M Ventures

Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.

A developer of IP-core for high-performance & efficient computing using Quasi-CMOS technology. NeoLogic delivers high Fan-in logic cells (6-32 inputs) that reduce circuit area, static power dissipation as well as circuit depth.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.

Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.

Metalenz, Inc. is a company focused on the research, development, and production of advanced optical components, particularly for consumer electronics such as mobile phones and computers. Founded in 2016 and based in Weston, Massachusetts, with an additional office in San Francisco, the company specializes in novel optical elements that utilize structured Huygens' surfaces, a type of metamaterial. These meta-optics enable the creation of ultra-thin planar optics that facilitate high-resolution full-color imaging. By providing smaller and lighter lens alternatives, Metalenz aims to enhance the capabilities of electronic devices while promoting miniaturization in optical design, thus supporting a range of high-volume applications, including automotive technologies.

Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.

NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.

Neurable Inc. develops an artificial intelligence software that allows people to control software and objects with their brain activity. Its technology enables people to play games, operate toys, and drive a full-sized car using their brain activity; and allows for virtual reality and augmented reality applications. Neurable Inc. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

NUGGS is a plant-based chicken nugget developed by SIMULATE, an early-stage biotechnology company founded by Ben Pasternak in 2019. Utilizing advanced soy protein technology, NUGGS replicates the texture and flavor of traditional chicken nuggets while offering nutritional advantages, including 13 grams of protein and 10 grams of fat, making it lower in fat and cholesterol-free compared to animal-based options. NUGGS operates similarly to a technology startup, with a commitment to continuous improvement based on consumer feedback, akin to software updates. Since its launch, NUGGS has rapidly gained popularity, positioning itself as a disruptive force in the animal-based meat industry. SIMULATE is also expanding its product line, with plans for additional offerings in the near future.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, founded in 2014. The company focuses on discovering and developing small molecule drugs that specifically target functional three-dimensional RNA structures to treat various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools to identify novel small molecules that can inhibit the production of disease-associated proteins. By integrating artificial intelligence and machine learning capabilities, the company aims to enhance its understanding of RNA biology and its implications in health and disease. Ribometrix operates scientific offices in a renovated space in Durham, with additional locations in Chapel Hill and Boston.

ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

aveni, Inc. specializes in advanced metallization technologies for semiconductor applications, particularly in damascene through silicon vias and micro-electromechanical systems (MEMS). The company offers two primary technologies: Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), which is designed for non-conductive substrates. Both technologies are instrumental in enhancing device performance and yield, making them essential for modern semiconductor manufacturing. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA), aveni has established partnerships with various research and development centers, as well as leading global equipment and device manufacturers. The company operates from its headquarters in Massy, France, and leverages a skilled team of scientists and engineers with expertise in surface science, electrochemistry, and materials science to drive innovation in the field.

Peratech Holdco Limited is a company specializing in force-sensing solutions, primarily through its patented Quantum Tunnelling Composite (QTC) technology. This innovative material transitions from an insulator to a conductor based on the applied force, allowing for precise and repeatable sensing even under challenging conditions. Peratech offers a range of products, including standard QTC sensors for single-point and multi-touch applications, as well as a Touch Development Kit for prototyping. The company also provides custom solutions, including sensor design, mechanical integration, and embedded electronics. Its technology is utilized across various sectors, including consumer electronics, automotive systems, smart home devices, and industrial controls, enabling intuitive human-machine interactions. Founded in 1996 and headquartered in Richmond, United Kingdom, Peratech has expanded its presence with additional offices in South Korea and Sweden. The company's commitment to innovation is reflected in its award-winning products, such as the 3D Multi-Touch Matrix Sensor, which has garnered recognition for its engineering excellence.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The company’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

Synaffix BV is a biotechnology company based in Oss, the Netherlands, focused on developing advanced antibody-drug conjugate (ADC) technology platforms for oncology. Established in 2010, the company offers proprietary solutions such as GlycoConnect, which enables site-specific and stable conjugation of anti-cancer agents by modifying glycan anchor points on antibodies. Additionally, Synaffix provides HydraSpace, a linker technology designed to enhance payload solubility and reduce aggregation in ADCs, alongside a metal-free click chemistry applicable across various sectors, including pharmaceuticals and academia. As a clinical-stage enterprise, Synaffix employs a technology out-licensing business model and engages in research collaborations with other organizations to facilitate the development of competitive ADC products. Its patent portfolio extends protection for resulting products through at least 2035, bolstering its position in the biotechnology landscape.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.